Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.76 – $2.05
Volume4,096
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.86M
Price / earnings
—
Price / book
0.26×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.08×
Profitability
Earnings per share
-$23.95
Return on assets
-228%
Return on equity
-333.05%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.02×
Current ratio
2.47×
Quick ratio
2.47×
Cash ratio
0.08×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$5.72M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PPCB, quarterly periods
Line item
Q1 FY2027 Sep 30, 2026
Q4 FY2026 Jun 30, 2026
Q3 FY2026 Mar 31, 2026
Q2 FY2026 Dec 31, 2025
Q1 FY2026 Sep 30, 2025
Revenue
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
Selling, general and administrative
$2.44M
$3.08M
$6.23M
$3.63M
$262.13K
Research and development
$457.68K
$375.66K
$169.66K
$19.96K
$60.2K
Total operating expenses
$8.57M
$3.46M
$6.4M
$3.65M
$4.67M
Operating income
-$8.57M
-$3.46M
-$6.4M
-$3.65M
-$4.67M
Interest expense
-$18.24K
-$27.67K
-$38.27K
-$58.96K
-$305.65K
Income before taxes
-$8.59M
-$4.57M
-$6.36M
-$3.09M
-$4.84M
Income taxes
$0
$0
$0
$0
$0
Net income
-$8.59M
-$4.57M
-$6.36M
-$3.09M
-$4.84M
Net income attributable to common shareholders
-$8.59M
-$4.57M
-$6.36M
-$4.02M
-$4.84M
EBITDA
-$8.57M
-$3.46M
-$6.4M
-$3.65M
-$4.67M
Basic earnings per share
-$12.22
-$17.79
-$70.00
-$75.00
-$98.08
Diluted earnings per share
-$12.22
-$17.79
-$70.00
-$75.00
-$98.08
Recent news
Company coverage with links to the original publishers.
Propanc Biopharma is pursuing a strategic initiative to acquire Digital Asset Treasury (DAT) companies trading below their market cap to net asset value, aiming to diversify its asset base and create shareholder value.
Propanc Biopharma secured a strategic financing agreement with Hexstone Capital for up to $100 million, involving convertible preferred stock and warrants to support clinical pipeline development and digital asset treasury strategy.
Propanc Biopharma successfully closed a public offering of 1,000,000 shares at $4.00 per share, raising $4 Million and commencing trading on the Nasdaq Capital Market under the ticker PPCB.
Propanc Biopharma announced a public offering of 1 million shares at $4.00 per share, expecting to raise approximately $4 million. The company will use proceeds for working capital and has received approval to list on Nasdaq Capital Market.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.